These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20473185)

  • 1. Bayesian meta-analyses for comparative effectiveness and informing coverage decisions.
    Berry SM; Ishak KJ; Luce BR; Berry DA
    Med Care; 2010 Jun; 48(6 Suppl):S137-44. PubMed ID: 20473185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian approaches for comparative effectiveness research.
    Berry DA
    Clin Trials; 2012 Feb; 9(1):37-47. PubMed ID: 21878446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian methodology for the design and interpretation of clinical trials in critical care medicine: a primer for clinicians.
    Kalil AC; Sun J
    Crit Care Med; 2014 Oct; 42(10):2267-77. PubMed ID: 25226118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research.
    Duan N; Kravitz RL; Schmid CH
    J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S21-8. PubMed ID: 23849149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?
    Barold HS
    Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
    Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is evidence?
    Normand SL; McNeil BJ
    Stat Med; 2010 Aug; 29(19):1985-8; discussion 1996-7. PubMed ID: 20683888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator.
    Hlatky MA; Sanders GD; Owens DK
    Health Aff (Millwood); 2005; 24(1):42-51. PubMed ID: 15647214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Random-effects meta-analysis for systematic reviews of phase I clinical trials: Rare events and missing data.
    Kim MO; Wang X; Liu C; Dorris K; Fouladi M; Song S
    Res Synth Methods; 2017 Jun; 8(2):124-135. PubMed ID: 27285532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter defibrillators: an excellent case study.
    Stanton MS
    Health Aff (Millwood); 2005; 24(1):52-4. PubMed ID: 15647215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of adjusting for potential confounders in Bayesian hierarchical models synthesising evidence from randomised and non-randomised studies: an application comparing treatments for abdominal aortic aneurysms.
    McCarron CE; Pullenayegum EM; Thabane L; Goeree R; Tarride JE
    BMC Med Res Methodol; 2010 Jul; 10():64. PubMed ID: 20618973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials.
    Clayton GL; Smith IL; Higgins JPT; Mihaylova B; Thorpe B; Cicero R; Lokuge K; Forman JR; Tierney JF; White IR; Sharples LD; Jones HE
    Trials; 2017 May; 18(1):219. PubMed ID: 28506284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study.
    Connor JT; Luce BR; Broglio KR; Ishak KJ; Mullins CD; Vanness DJ; Fleurence R; Saunders E; Davis BR
    Clin Trials; 2013 Oct; 10(5):807-27. PubMed ID: 23983160
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.